Name: in vivo bioluminescent imaging of mammary tumors using ivis spectrum
Uploaded: 2009-04-29T00:00:00.000+00:00
Duration: 8 min 53 s
Description: Watch this Scientific Journal Video about In vivo Bioluminescent Imaging of Mammary Tumors Using IVIS Spectrum at JoVE.com

Una vasta gamma di linee di cellule tumorali che esprimono luciferasi può essere utilizzato per ricerca pre-clinica in modelli murini. Queste cellule sono forniti come un esenti da organismi patogeni cultura congelata, che sarà facilmente crescere in mezzi di comunicazione standard senza necessità di marcatori di selezione. Per il nostro esperimento, useremo il 4T1-luc2 murino linea di cellule tumorali mammarie, che esprime il gene della luciferasi, che funge da indicatore ottico di espressione genica o tumorgenesis in vivo. Useremo l&#39;espressione luciferasi per monitorare la crescita del tumore primario non invasivo, ma possono anche essere utilizzato per individuare e monitorare le lesioni metastatiche. Attività luciferasi deve essere verificata prima dell&#39;iniezione, e per fare questo, un pallone al 90% confluenti viene raccolto da tripsinizzazione e poi contati. 50.000 cellule vengono poi dispensati in un singolo pozzo della micropiastra e diluizioni seriali vengono eseguite. Luciferina viene aggiunto ai pozzetti a 150ug per ml e incubate per 2 minuti. La micropiastra possono essere esposte in IVIS o un lettore di piastre luminescente per determinare i livelli di espressione. Questa linea cellulare esprime fino a 6500 fotoni al secondo per cella, ma ogni livello di espressione di sopra di 500 fotoni al secondo per ogni cella può essere ripreso con successo in vivo. Ora che abbiamo le cellule di attività ottimale, si può procedere alla fase iniezione sottocutanea. Al fine di facilitare l&#39;individuazione ottimale del tumore, stiamo utilizzando un ceppo atimici immunocompromessi topo nudo. Prima dell&#39;iniezione, gli animali sono anestetizzati per effetto di anestesia profonda. Il prossimo iniettare fino a 250.000 cellule in PBS 100ul vengono iniettati per via sottocutanea nel fianco. Caricare le celle di una siringa da 1 ml e allegare a 26 gauge. Sollevare delicatamente la pelle con una pinza per fare una &quot;tenda&quot; e iniettare le cellule alla base. Le cellule nuovo apporto può essere ripreso immediatamente. In ogni sessione di imaging per un totale di 150 mg di Luciferin per kg di peso corporeo viene poi somministrato attraverso due iniezioni nella cavità peritoneale. In questo studio, gli animali vengono esposte 10 minuti dopo l&#39;iniezione Luciferin per garantire il flusso costante di fotoni. Vi mostreremo questo nella fase successiva. Cinetica luciferina può variare di giorno in giorno. In questo particolare modello, misura 10 minuti dopo l&#39;iniezione Luciferin ha dato un risultato in un intervallo di variabilità del 15%. Per il nostro esperimento useremo la spettro IVIS nel sistema di imaging in vivo utilizza un back-assottigliato Charge Coupled Device raffreddato a -90 ° C per ottenere la massima sensibilità. Per supportare la quantificazione assoluta, il sistema misura carica buio durante down-tempo e gestisce un auto-calibrazione durante l&#39;inizializzazione. Per iniziare imaging, inizializzare il sistema IVIS (un click) e impostare i parametri di imaging per l&#39;esperimento. Selezionare il campo visivo per il numero di animali che sono ripreso. Fino a 5 animali possono essere tenuti nello strumento usando il collettore integrale anestetico. Il palcoscenico è alla temperatura costante di 37 ° C per mantenere la temperatura corporea negli animali. Una porta ECG è previsto per monitorare la salute degli animali durante le procedure di stress. In Living software Image, tempo di esposizione, f-stop e pixel binning può essere ottimizzato in base al livello di espressione della linea cellulare. Queste impostazioni possono essere modificate in qualsiasi momento durante un esperimento senza impattare il risultato quantitativo. IVIS acquisisce un&#39;immagine fotografica dell&#39;animale a luce bianca e un segnale quantitativo bioluminescente o fluorescenti, che si sovrappone l&#39;immagine. Il segnale bioluminescente è espressa in fotoni al secondo e visualizzato come una mappa di intensità. La visualizzazione dell&#39;immagine viene regolata per fornire un contrasto ottimale e la risoluzione dell&#39;immagine senza influire quantificazione. Luminescenza dalle cellule può essere misurata nel sito di iniezione con una regione di strumento di interesse. Dati di misura sono visualizzati nella tabella con tutti i parametri sperimentali relativi alla cattura delle immagini che possono essere salvati o esportati per analisi Più immagini possono essere acquisite e confrontati negli studi longitudinali relativi secondi o mesi a seconda della natura di questo esperimento. Noi misurerà il flusso di fotoni dal tumore al tempo zero e monitorare per 4 settimane con immagini a intervalli bi-settimanale. Flusso di fotoni dal tumore è proporzionale al numero di cellule vive che esprimono in modo luciferasi bioluminescenza correla direttamente con le dimensioni del tumore. A 5 giorni dopo l&#39;impianto del tumore non è ancora palpabile, ma le cellule possono essere quantificati attraverso la bioluminescenza e il tumore è visto essere in fase di crescita. In questa fase il segnale di bioluminescenza è molto stronger. Il tempo di esposizione, f-stop e binning pixel può essere regolata in modo che l&#39;immagine è chiara e la fotocamera non satura. IVIS compensa automaticamente i cambiamenti nella raccolta luce quindi queste misure possono essere confrontati con quelli raccolti in precedenza e in seguito all&#39;esperimento. A 7 giorni dopo l&#39;impianto tumori sono palpabili per la prima volta e bioluminescenza misura ha già generato 7 giorni di dati. A 28 giorni dopo l&#39;impianto, i tumori stanno diventando necrotiche e le cellule cominciano a morire. Dimensioni del tumore stimato pinza misura non cambia sensibilmente, ma luminescenza dal tumore diminuisce indicare la morte cellulare. Misure pinza e misurazione bioluminescenza può essere continuato fino a quando un endpoint umano è raggiunto. Necrosi tumorale a causa di regimi di ipossia o trattamento sarà indicata da bioluminescenza ridotto anche se non ridurre la massa tumorale.

Vorrei assicurare che tutti gli esperimenti effettuati per produrre la Gazzetta di Visualizzato articolo esperimenti sono stati condotti nel rispetto del protocollo Animal 060 approvato dalla cura degli animali e utilizzo Comitato Istituzionale (IACUC) a pinza Life Sciences, Alameda CA Jae Kim, Ph . D., presidente IACUC, Caliper Life Sciences.

in vivo bioluminescent imaging of mammary tumors using ivis spectrum

4T1 cellule del tumore mammario del topo può essere impiantato sottocute nel nu / nu topi di formare tumori palpabile in 15 a 20 giorni. Questo modello di xenotrapianto sistema tumore è prezioso per la pre-clinica nella valutazione in vivo di composti antitumorali putativo. La linea di cellule 4T1 è stato progettato per esprimere costitutivamente il gene della luciferasi lucciola (luc2). Quando topi portatori 4T1-luc2 tumori sono iniettati con Luciferin i tumori emettono un segnale visivo luce che può essere controllata mediante un sistema di imaging ottico sensibile come la Spectrum IVIS. Il flusso di fotoni dal tumore è proporzionale al numero di celle che emettono luce e il segnale può essere misurato per controllare la crescita tumorale e lo sviluppo. IVIS è calibrato per consentire la quantificazione assoluta del segnale bioluminescente e gli studi longitudinali possono essere eseguite per molti mesi e su diversi ordini di grandezza del segnale senza compromettere il risultato quantitativo. La crescita tumorale può essere monitorato per diversi giorni dalla bioluminescenza prima le dimensioni del tumore diventa palpabile e misurabile con i tradizionali mezzi fisici. Tale monitoraggio in grado di fornire una rapida panoramica eventi precoci nello sviluppo del tumore o portare a brevi procedure sperimentali. Morte delle cellule tumorali e la necrosi a causa di un trattamento ipossia o farmaco è indicato all&#39;inizio di una riduzione del segnale bioluminescente. Questa morte cellulare può non essere accompagnata da una riduzione delle dimensioni del tumore, misurato per mezzo fisico. La capacità di vedere eventi precoci nella necrosi tumorale ha un impatto significativo sulla selezione e lo sviluppo di agenti terapeutici. L&#39;imaging quantitativo della crescita tumorale mediante IVIS fornisce quantificazione precisa e accelera il processo sperimentale per generare i risultati.

Watch this Scientific Journal Video about In vivo Bioluminescent Imaging of Mammary Tumors Using IVIS Spectrum at JoVE.com

In vivo Bioluminescent Imaging of Mammary Tumors Using IVIS Spectrum

Mammaria cellule tumorali che esprimono luciferasi sono impiantato per via sottocutanea nei topi ed è visualizzato mediante imaging ottico per monitorare la crescita e lo sviluppo del tumore non invasivo in uno studio longitudinale.

In vivo Bioluminescent Imaging dei tumori mammari che usano lo spettro IVIS

4T1 mouse mammary tumor cells can be implanted sub-cutaneously in nu/nu mice to form palpable tumors in 15 to 20 days. This xenograft tumor model system ...

in-vivo-bioluminescent-imaging-of-mammary-tumors-using-ivis-spectrum

Universidad de Cartagena UDEC

Research

JoVE Journal

Biology

In vivo Bioluminescent Imaging of Mammary Tumors Using IVIS Spectrum

47.0K Views.  Caliper Life Sciences.  中文 

Video: In vivo Bioluminescent Imaging of Mammary Tumors Using IVIS Spectrum

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging

Transplantation models using human brain tumor cells have served an essential function in neuro-oncology research for many years. In the past, the most commonly used procedure for human tumor xenograft establishment consisted of the collection of cells from culture flasks, followed by the subcutaneous injection of the collected cells in immunocompromised mice. Whereas this approach still sees frequent use in many laboratories, there has been a significant shift in emphasis over the past decade towards orthotopic xenograft establishment, which, in the instance of brain tumors, requires tumor cell injection into appropriate neuroanatomical structures. Because intracranial xenograft establishment eliminates the ability to monitor tumor growth through direct measurement, such as by use of calipers, the shift in emphasis towards orthotopic brain tumor xenograft models has necessitated the utilization of non-invasive imaging for assessing tumor burden in host animals. Of the currently available imaging methods, bioluminescence monitoring is generally considered to offer the best combination of sensitivity, expediency, and cost. Here, we will demonstrate procedures for orthotopic brain tumor establishment, and for monitoring tumor growth and response to treatment when testing experimental therapies.

Luciferase-modified human brain tumor xenografts can be established intracranially in athymic mice, with subsequent monitoring of tumor growth and response to therapy using bioluminescence imaging. In combination with survival analysis, bioluminescence monitoring is an essential research tool for pre-clinical testing of therapies being considered for treating brain tumors.

Stabilire intracranica xenotrapianti Brain Tumor Con successiva analisi della crescita tumorale e risposta alla terapia con Imaging bioluminescenza

Transplantation models using human brain tumor cells have served an essential function in neuro-oncology research for many years. In the past, the most ...

Ricerca

Neuroscienze

Monitoring Tumor Metastases and Osteolytic Lesions with Bioluminescence and Micro CT Imaging

Following intracardiac delivery of MDA-MB-231-luc-D3H2LN cells to Nu/Nu mice, systemic metastases developed in the injected animals. Bioluminescence imaging using IVIS Spectrum was employed to monitor the distribution and development of the tumor cells following the delivery procedure including DLIT reconstruction to measure the tumor signal and its location.
Development of metastatic lesions to the bone tissues triggers osteolytic activity and lesions to tibia and femur were evaluated longitudinally using micro CT. Imaging was performed using a Quantum FX micro CT system with fast imaging and low X-ray dose. The low radiation dose allows multiple imaging sessions to be performed with a cumulative X-ray dosage far below LD50. A mouse imaging shuttle device was used to sequentially image the mice with both IVIS Spectrum and Quantum FX achieving accurate animal positioning in both the bioluminescence and CT images. The optical and CT data sets were co-registered in 3-dimentions using the Living Image 4.1 software. This multi-mode approach allows close monitoring of tumor growth and development simultaneously with osteolytic activity.

An experimental mouse model of bone metastasis was established following intracardiac delivery of luciferase expressing mammary tumor cells. Tumor development and resulted osteolytic lesion were monitored longitudinally with bioluminescence and micro CT imaging.

Monitoraggio metastasi tumorali e lesioni osteolitiche con bioluminescenza e Micro CT Imaging

Following intracardiac delivery of MDA-MB-231-luc-D3H2LN cells to Nu/Nu mice, systemic metastases developed in the injected animals. Bioluminescence ...

Medicina

In vivo Bioluminescence Imaging of Tumor Hypoxia Dynamics of Breast Cancer Brain Metastasis in a Mouse Model

It is well recognized that tumor hypoxia plays an important role in promoting malignant progression and affecting therapeutic response negatively. There is little knowledge about in situ, in vivo, tumor hypoxia during intracranial development of malignant brain tumors because of lack of efficient means to monitor it in these deep-seated orthotopic tumors. Bioluminescence imaging (BLI), based on the detection of light emitted by living cells expressing a luciferase gene, has been rapidly adopted for cancer research, in particular, to evaluate tumor growth or tumor size changes in response to treatment in preclinical animal studies. Moreover, by expressing a reporter gene under the control of a promoter sequence, the specific gene expression can be monitored non-invasively by BLI. Under hypoxic stress, signaling responses are mediated mainly via the hypoxia inducible factor-1&alpha; (HIF-1&alpha;) to drive transcription of various genes. Therefore, we have used a HIF-1&alpha; reporter construct, 5HRE-ODD-luc, stably transfected into human breast cancer MDA-MB231 cells (MDA-MB231/5HRE-ODD-luc). In vitro HIF-1&alpha; bioluminescence assay is performed by incubating the transfected cells in a hypoxic chamber (0.1% O2) for 24 hr before BLI, while the cells in normoxia (21% O2) serve as a control. Significantly higher photon flux observed for the cells under hypoxia suggests an increased HIF-1&alpha; binding to its promoter (HRE elements), as compared to those in normoxia. Cells are injected directly into the mouse brain to establish a breast cancer brain metastasis model. In vivo bioluminescence imaging of tumor hypoxia dynamics is initiated 2 wks after implantation and repeated once a week. BLI reveals increasing light signals from the brain as the tumor progresses, indicating increased intracranial tumor hypoxia. Histological and immunohistochemical studies are used to confirm the in vivo imaging results. Here, we will introduce approaches of in vitro HIF-1&alpha; bioluminescence assay, surgical establishment of a breast cancer brain metastasis in a nude mouse and application of in vivo bioluminescence imaging to monitor intracranial tumor hypoxia.

In vivo Bioluminescence Imaging of Tumor Hypoxia Dynamics of Breast Cancer Brain Metastasis in a Mouse Model

Bioluminescence imaging of hypoxia inducible factor-1&alpha; activity is applied to monitor intracranial tumor hypoxia development in a breast cancer brain metastasis mouse model.

In Imaging bioluminescenza in vivo di Dinamica Tumore ipossia di metastasi cerebrali cancro al seno in un modello murino

It is well recognized that tumor hypoxia plays an important role in promoting malignant progression and affecting therapeutic response negatively. There ...

In vivo Dual Substrate Bioluminescent Imaging

Our understanding of how and when breast cancer cells transit from established primary tumors to metastatic sites has increased at an exceptional rate since the advent of in vivo bioluminescent imaging technologies 1-3. Indeed, the ability to locate and quantify tumor growth longitudinally in a single cohort of animals to completion of the study as opposed to sacrificing individual groups of animals at specific assay times has revolutionized how researchers investigate breast cancer metastasis. Unfortunately, current methodologies preclude the real-time assessment of critical changes that transpire in cell signaling systems as breast cancer cells (i) evolve within primary tumors, (ii) disseminate throughout the body, and (iii) reinitiate proliferative programs at sites of a metastatic lesion. However, recent advancements in bioluminescent imaging now make it possible to simultaneously quantify specific spatiotemporal changes in gene expression as a function of tumor development and metastatic progression via the use of dual substrate luminescence reactions. To do so, researchers take advantage for two light-producing luciferase enzymes isolated from the firefly (Photinus pyralis) and sea pansy (Renilla reniformis), both of which react to mutually exclusive substrates that previously facilitated their wide-spread use in in vitro cell-based reporter gene assays 4. Here we demonstrate the in vivo utility of these two enzymes such that one luminescence reaction specifically marks the size and location of a developing tumor, while the second luminescent reaction serves as a means to visualize the activation status of specific signaling systems during distinct stages of tumor and metastasis development. Thus, the objectives of this study are two-fold. First, we will describe the steps necessary to construct dual bioluminescent reporter cell lines, as well as those needed to facilitate their use in visualizing the spatiotemporal regulation of gene expression during specific steps of the metastatic cascade. Using the 4T1 model of breast cancer metastasis, we show that the in vivo activity of a synthetic Smad Binding Element (SBE) promoter was decreased dramatically in pulmonary metastasis as compared to that measured in the primary tumor 4-6. Recently, breast cancer metastasis was shown to be regulated by changes within the primary tumor microenvironment and reactive stroma, including those occurring in fibroblasts and infiltrating immune cells 7-9. Thus, our second objective will be to demonstrate the utility of dual bioluminescent techniques in monitoring the growth and localization of two unique cell populations harbored within a single animal during breast cancer growth and metastasis.

In vivo Dual Substrate Bioluminescent Imaging

Herein we describe the methods to construct, visualize, and quantify the bioluminescent reactions of both firefly and renilla luciferase enzymes expressed in metastatic breast cancer cells during their growth and metastasis in vivo.

In vivo doppio substrato Bioluminescent Imaging

Our understanding of how and when breast cancer cells transit from established primary tumors to metastatic sites has increased at an exceptional rate ...

Intracranial Implantation with Subsequent 3D In Vivo Bioluminescent Imaging of Murine Gliomas

The mouse glioma 261 (GL261) is recognized as an in vivo model system that recapitulates many of the features of human glioblastoma multiforme (GBM). The cell line was originally induced by intracranial injection of 3-methyl-cholantrene into a C57BL/6 syngeneic mouse strain 1; therefore, immunologically competent C57BL/6 mice can be used. While we use GL261, the following protocol can be used for the implantation and monitoring of any intracranial mouse tumor model. GL261 cells were engineered to stably express firefly luciferase (GL261-luc). We also created the brighter GL261-luc2 cell line by stable transfection of the luc2 gene expressed from the CMV promoter. C57BL/6-cBrd/cBrd/Cr mice (albino variant of C57BL/6) from the National Cancer Institute, Frederick, MD were used to eliminate the light attenuation caused by black skin and fur. With the use of albino C57BL/6 mice; in vivo imaging using the IVIS Spectrum in vivo imaging system is possible from the day of implantation (Caliper Life Sciences, Hopkinton, MA). The GL261-luc and GL261-luc2 cell lines showed the same in vivo behavior as the parental GL261 cells. Some of the shared histological features present in human GBMs and this mouse model include: tumor necrosis, pseudopalisades, neovascularization, invasion, hypercellularity, and inflammation 1.
Prior to implantation animals were anesthetized by an intraperitoneal injection of ketamine (50 mg/kg), xylazine (5 mg/kg) and buprenorphine (0.05 mg/kg), placed in a stereotactic apparatus and an incision was made with a scalpel over the cranial midline. A burrhole was made 0.1mm posterior to the bregma and 2.3mm to the right of the midline. A needle was inserted to a depth of 3mm and withdrawn 0.4mm to a depth of 2.6mm. Two &mu;l of GL261-luc or GL261-luc2 cells (107 cells/ml) were infused over the course of 3 minutes. The burrhole was closed with bonewax and the incision was sutured.
Following stereotactic implantation the bioluminescent cells are detectable from the day of implantation and the tumor can be analyzed using the 3D image reconstruction feature of the IVIS Spectrum instrument. Animals receive a subcutaneous injection of 150&mu;g luciferin /kg body weight 20 min prior to imaging. Tumor burden is quantified using mean tumor bioluminescence over time. Tumor-bearing mice were observed daily to assess morbidity and were euthanized when one or more of the following symptoms are present: lethargy, failure to ambulate, hunched posture, failure to groom, anorexia resulting in &gt;10% loss of weight. Tumors were evident in all of the animals on necropsy.

Intracranial Implantation with Subsequent 3D In Vivo Bioluminescent Imaging of Murine Gliomas

Intracranial implantation of GL261 cells into C57BL/6 mice produces malignant gliomas that recapitulate many of the hallmarks of human glioblastoma multiforme. We used GL261 cells stably expressing luciferase to allow us to use in vivo imaging to follow tumor progression. The surgery and 3D in vivo imaging are demonstrated.

Impianto intracranica con 3D successivi In Vivo Bioluminescent Imaging dei gliomi Murine

The mouse glioma 261 (GL261) is recognized as an in vivo model system that recapitulates many of the features of human glioblastoma multiforme (GBM). The ...

Bioluminescent Bacterial Imaging In Vivo

This video describes the use of whole body bioluminesce imaging (BLI) for the study of bacterial trafficking in live mice, with an emphasis on the use of bacteria in gene and cell therapy for cancer. Bacteria present an attractive class of vector for cancer therapy, possessing a natural ability to grow preferentially within tumors following systemic administration. Bacteria engineered to express the lux gene cassette permit BLI detection of the bacteria and concurrently tumor sites. The location and levels of bacteria within tumors over time can be readily examined, visualized in two or three dimensions. The method is applicable to a wide range of bacterial species and tumor xenograft types. This article describes the protocol for analysis of bioluminescent bacteria within subcutaneous tumor bearing mice. Visualization of commensal bacteria in the Gastrointestinal tract (GIT) by BLI is also described. This powerful, and cheap, real-time imaging strategy represents an ideal method for the study of bacteria in vivo in the context of cancer research, in particular gene therapy, and infectious disease. This video outlines the procedure for studying lux-tagged E. coli in live mice, demonstrating the spatial and temporal readout achievable utilizing BLI with the IVIS system.

Bioluminescent Bacterial Imaging In Vivo

This article describes the administration of lux-tagged bacteria to mice and subsequent in vivo analysis using IVIS bioluminescence imaging.

Bioluminescent Imaging batterica<em&gt; In Vivo</em

This video describes the use of whole body bioluminesce imaging (BLI) for the study of bacterial trafficking in live mice, with an emphasis on the use of ...

Immunologia e infezioni

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Breast cancer is a frequent heterogeneous malignancy and the second leading cause of mortality in women, mainly due to distant organ metastasis. Several animal models have been generated, including the widely used orthotopic mouse models, where cancer cells are injected into the mammary fat pad. However, these models cannot help monitor tumor growth kinetics and metastatic colonization. Cutting-edge tools to monitor cancer cells in real time in mice will significantly advance the understanding of tumor biology. 
Here, breast cancer cell lines stably expressing luciferase and green fluorescent protein (GFP) were established. Specifically, this technique contains two sequential steps initiated by measuring the luciferase activity in vitro and followed by the implantation of the cancer cells into mammary fat pads of nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mice. After the injection, both the tumor growth and metastatic colonization are monitored in real time by the noninvasive bioluminescence imaging system. Then, the quantification of GFP-expressing metastases in the lungs will be examined by fluorescence microscopy to validate the observed bioluminescence results. This sophisticated system combining luciferase and fluorescence-based detection tools evaluates cancer metastasis in vivo, which has great potential for use in breast cancer therapeutics and disease management.

Here, we describe a noninvasive monitoring method involving luciferase and green fluorescent protein expression in various breast cancer cell lines. This protocol provides a technique to monitor tumor formation and metastatic colonization in real time in mice.

Monitoraggio della crescita del cancro al seno e della formazione di colonie metastatiche nei topi utilizzando la bioluminescenza

Breast cancer is a frequent heterogeneous malignancy and the second leading cause of mortality in women, mainly due to distant organ metastasis. Several ...

Ricerca sul cancro

In Vivo Imaging to Measure Spontaneous Lung Metastasis of Orthotopically-injected Breast Tumor Cells

Metastasis remains the primary cause of cancer-related death. The succession of events that characterize the metastatic cascade presents multiple opportunities for therapeutic intervention, and the ability to accurately model them in mice is critical to evaluate their effects. Here, a step-by-step protocol is presented for the establishment of orthotopic primary breast tumors and the subsequent monitoring of the establishment and growth of metastatic lesions in the lung using in vivo bioluminescence imaging. This methodology allows for the evaluation of treatment or its biological effects along the entire range of metastatic development, from primary tumor escape to outgrowth in the lungs. Breast orthotopic tumors are generated in mice via injection of a luciferase-labeled cell suspension in the 4th mammary gland. Tumors are allowed to grow and disseminate for a specific amount of time and are then surgically resected. Upon resection, spontaneous lung metastasis is detected, and the growth over time is monitored using in vivo bioluminescence imaging. At the desired experimental endpoint, lung tissue can be collected for downstream analysis. The treatment of established, clinically evident metastasis is critical to improve outcomes for stage IV cancer patients, and it can be evaluated through tail vein models of experimental lung metastasis. However, metastatic dissemination occurs early in breast cancer, and many patients have latent, subclinical disseminated disease after surgery. Utilization of spontaneous models such as this one provides the opportunity to study the whole spectrum of the disease, especially the systemic effects driven by treatment of the primary tumor such as pre-metastatic niche priming, and evaluate treatments on dormant and subclinical disease after surgery.

<meta charset="utf8"></head><body>Imaging in vivo per misurare le metastasi polmonari spontanee di cellule tumorali mammarie iniettate ortotopicamente

The manuscript describes a methodology for the establishment as well as longitudinal growth monitoring of spontaneous lung metastasis from orthotopically-injected breast tumors, amenable to intervention at all stages of the metastatic cascade.

In vivo Imaging per misurare le metastasi polmonari spontanee di cellule tumorali mammarie iniettate ortotopicamente

Metastasis remains the primary cause of cancer-related death. The succession of events that characterize the metastatic cascade presents multiple ...

Combined In vivo Optical and &#181;CT Imaging to Monitor Infection, Inflammation, and Bone Anatomy in an Orthopaedic Implant Infection in Mice

Multimodality imaging has emerged as a common technological approach used in both preclinical and clinical research. Advanced techniques that combine in vivo optical and &#956;CT imaging allow the visualization of biological phenomena in an anatomical context. These imaging modalities may be especially useful to study conditions that impact bone. In particular, orthopaedic implant infections are an important problem in clinical orthopaedic surgery. These infections are difficult to treat because bacterial biofilms form on the foreign surgically implanted materials, leading to persistent inflammation, osteomyelitis and eventual osteolysis of the bone surrounding the implant, which ultimately results in implant loosening and failure. Here, a mouse model of an infected orthopaedic prosthetic implant was used that involved the surgical placement of a Kirschner-wire implant into an intramedullary canal in the femur in such a way that the end of the implant extended into the knee joint. In this model, LysEGFP mice, a mouse strain that has EGFP-fluorescent neutrophils, were employed in conjunction with a bioluminescent Staphylococcus aureus strain, which naturally emits light. The bacteria were inoculated into the knee joints of the mice prior to closing the surgical site. In vivo bioluminescent and fluorescent imaging was used to quantify the bacterial burden and neutrophil inflammatory response, respectively. In addition, &#956;CT imaging was performed on the same mice so that the 3D location of the bioluminescent and fluorescent optical signals could be co-registered with the anatomical &#956;CT images. To quantify the changes in the bone over time, the outer bone volume of the distal femurs were measured at specific time points using a semi-automated contour based segmentation process. Taken together, the combination of in vivo bioluminescent/fluorescent imaging with &#956;CT imaging may be especially useful for the noninvasive monitoring of the infection, inflammatory response and anatomical changes in bone over time.

Combined In vivo Optical and  &#181;CT Imaging to Monitor Infection, Inflammation, and Bone Anatomy in an Orthopaedic Implant Infection in Mice

Combined optical and &#956;CT imaging in a mouse model of orthopaedic implant infection, utilizing a bioluminescent engineered strain of Staphylococcus aureus, provided the capability to noninvasively and longitudinally monitor the dynamics of the bacterial infection, as well as the corresponding inflammatory response and anatomical changes in the bone.

Combinato<em&gt; In vivo</em&gt; Optical e μCT Imaging Monitor per infezione, infiammazione, e Bone Anatomy in una infezione ortopedica impianto in topi

Multimodality imaging has emerged as a common technological approach used in both preclinical and clinical research. Advanced techniques that combine in ...

In vivo Bioluminescent Imaging dei tumori mammari che usano lo spettro IVIS

Trascrizione

Riepilogo

Esplora Altri Video

Capitoli in questo video

Stabilire intracranica xenotrapianti Brain Tumor Con successiva analisi della crescita tumorale e risposta alla terapia con Imaging bioluminescenza

Monitoraggio metastasi tumorali e lesioni osteolitiche con bioluminescenza e Micro CT Imaging

In Imaging bioluminescenza in vivo di Dinamica Tumore ipossia di metastasi cerebrali cancro al seno in un modello murino

In vivo doppio substrato Bioluminescent Imaging

Impianto intracranica con 3D successivi In Vivo Bioluminescent Imaging dei gliomi Murine

Bioluminescent Imaging batterica

Monitoraggio della crescita del cancro al seno e della formazione di colonie metastatiche nei topi utilizzando la bioluminescenza

In vivo Imaging per misurare le metastasi polmonari spontanee di cellule tumorali mammarie iniettate ortotopicamente

In vivo Imaging per misurare le metastasi polmonari spontanee di cellule tumorali mammarie iniettate ortotopicamente

Combinato